BioElectronics Corporation (OTC: BIEL), a leader in bioelectronic, drug-free pain therapy, announced the imminent commercial launch of ActiPatch in Taiwan by its appointed distributor, Aphrodite Medical Group. The move expands the company's footprint into a new market, challenging conventional pain management approaches with a non-invasive, drug-free device.
ActiPatch is a US FDA-cleared medical device that delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device provides up to 720 hours of continuous therapy and is designed for extended wear, including during sleep, offering a practical alternative to pharmaceuticals, which often carry risks of addiction and side effects.
“The appointment of Aphrodite Medical Group establishes a strong commercial foundation for ActiPatch in Taiwan,” said Kelly Whelan, CEO of BioElectronics Corporation. “Their clinical infrastructure and commitment to advanced patient care make them a capable partner to introduce and scale this therapy in a meaningful way.”
The initial shipment of ActiPatch units has been completed, positioning the product for a coordinated market launch in Q2 2026, as noted in the press release. The rollout will focus on musculoskeletal pain management, with opportunities for expansion across additional clinical applications over time.
“We are pleased to bring ActiPatch to Taiwan as part of our commitment to delivering innovative, patient-centered therapies,” said Yang Pei-Hsien, Vice President of Aphrodite Medical Group. “This technology aligns with the growing demand for safe, effective, and drug-free pain management options.”
The Taiwan launch reinforces BioElectronics’ strategy to expand through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies. The company’s products, including ActiPatch and RecoveryRx, are FDA-cleared, non-invasive, and drug-free, using pulsed shortwave technology to treat pain and support recovery.
Aphrodite Medical Group, a Taiwan-based healthcare organization, offers a comprehensive range of medical and wellness services through a network of clinics and providers. Their partnership with BioElectronics is expected to facilitate patient access and physician engagement across Taiwan.
This expansion is significant as it provides a drug-free alternative in a region where pain management often relies on medications. With the opioid crisis highlighting the dangers of pharmaceutical pain relievers, ActiPatch offers a safe, non-addictive option. The device's ability to provide continuous therapy for up to 720 hours per unit makes it a cost-effective and convenient solution for patients with chronic pain.
By introducing ActiPatch to Taiwan, BioElectronics aims to disrupt traditional pain management paradigms and address the growing demand for non-pharmacological interventions. The success of this launch could pave the way for further expansion into other Asian markets, potentially transforming pain care across the region.
